Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
NGM Biopharmaceuticals, Inc. - Common Stock
(NQ:
NGM
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
1.550 (545)
Ask (Size)
1.610 (1)
Prev. Close
1.540
Today's Range
N/A - N/A
52wk Range
0.8288 - 2.200
Shares Outstanding
78,049,340
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NGM Bio Announces Closing of Tender Offer
April 05, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
March 19, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Performance
More News
Read More
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
March 13, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Looking Into NGM Biopharmaceuticals's Recent Short Interest
January 19, 2024
Via
Benzinga
Why NGM Biopharmaceuticals Stock Is Blasting Higher
January 02, 2024
Via
Benzinga
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
March 11, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
February 27, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Via
Benzinga
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
February 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 26, 2024
Via
Benzinga
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
February 26, 2024
From
Halper Sadeh LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), NGM Biopharmaceuticals, Inc. (Nasdaq – NGM), VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT)
February 26, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
February 26, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
February 20, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 17, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 09, 2024
Via
Benzinga
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
January 09, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
December 29, 2023
Via
Benzinga
B. Riley Securities Maintains Buy Rating for NGM Biopharmaceuticals: Here's What You Need To Know
November 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
November 20, 2023
Via
Benzinga
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
November 13, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in Upcoming Investor Conferences
November 07, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright